Not Frustrated.Sunrise is on track to complete enrollment on time. Obviously, the only really important fact we needed to hear at the CC. Many of us expect major success from Sunrise. Now we know there will be no delay in the trial. Very cool.
The much-maligned Peregrine management is expanding Avid to accommodate ever growing business. More business means more money means less dilution. Sounds like good news.
Peregrine is expanding late phase clinical trial in lung and breast cancer. Obviously management believes the potential value well exceeds the cost. Sounds like more good news.
Memorial Sloan Kettering taking on a paid research deal with Peregrine. Gee, probably the most famous cancer research institute in the United States. How much more good news could we ask for.
Chris Keenan is gone. I wish him well, but did not find him at all friendly.
The share price does suck, but the movement in company fundamental processes looks more promising than any time in Peregrine history.
GLTA, especially Bavi-arm Sunrise patients.
Paul
News 
Market Data 
Discover 
AI
